When a Drug Launch Moves, the Business Changes Too
Roche's changing European plans raise questions about drug pricing, reimbursement and launch timing. Ron Lanton examines what these decisions mean for biotechnology companies and investors, following recent reporting by Maggie Fick in Endpoints News.
https://endpoints.news/roches-changing-plans-show-how-mfn-is-complicating-european-drug-launches/
The Legal Questions Behind a Pharmaceutical Manufacturing Move
A pharmaceutical manufacturing move involves real estate, FDA compliance, incentives, trade rules, contracts and long-term operational risk.